SVStefan Verlohren

Stefan Verlohren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefan Verlohren has a total of 449 co-authors. Here are the top co-authors by number of shared publications:

  • Wolfgang Henrich

    Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Obstetrics, Berlin, Germany

    23 shared publications
  • Florian Herse

    Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

    15 shared publications
  • Holger Stepan

    Department of Obstetrics, University Hospital Leipzig, Leipzig, Germany

    14 shared publications
  • Harald Zeisler

    12 shared publications
  • Alberto Galindo

    Fetal Medicine Unit - Maternal and Child Health and Development Network, Department of Obstetrics and Gynaecology, University Hospital 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain

    10 shared publications
  • Dominik Nikolaus Müller

    Experimental and Clinical Research Center (ECRC) A Cooperation of Charité – Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine (MDC) Berlin Germany

    10 shared publications

Latest Publications

  • Therapeutic Interventions for Preeclampsia: Integrating Placental and Maternal Perspectives

    by Shrreya S. Sudade, Luisa Wallentowitz, Emma M. Giesen, Evelyn A. Huhn, Ann‐Christin Tallarek, Sandra M. Blois, Stefan Verlohren

    Preeclampsia (PE), a hypertensive disorder of pregnancy, is one of the leading causes of maternal and fetal mortality worldwide. Beyond the immediate pregnancy impact, it is also associated with increased long‐term risks in both the mother and the offspring. Currently, no causal therapy exists. Consequently, the complex and heterogeneous nature of PE necessitates the exploration of novel therapeutic targets to improve maternal and fetal outcomes. This review summarizes models of pathogenesis in PE, particularly the two‐stage model of the development of PE, where the placenta is suggested to be the main source of the disease, and the postulation that PE is a result of dysfunction of the maternal cardiovascular system. We explore novel therapeutic approaches, considering the underlying mechanisms such as galectin‐13, placental growth factor, therapeutic plasma exchange (TPE), trophoblast‐targeted nanomedicine, gene therapy, nitric oxide donors, endothelin receptor antagonists, and mesenchymal stem cells. Challenges in translating preclinical findings to clinical practice, including animal model limitations and ethical considerations, are discussed. Finally, this review integrates current treatment options, discusses their limitations, highlights ethical considerations, and outlines future directions for PE therapeutics, emphasizing the need for personalized therapeutic strategies.

  • Open Access

    Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions

    by Luisa Wallentowitz, Mariana G Garcia, Catalina Atorrasagasti, Charlotte Harms, Evelyn A Huhn, Pia Roser, Stefan Verlohren, Emma M Giesen, Sandra M Blois

    The global epidemic of overweight and obesity threatens gynecological and reproductive health, necessitating effective therapeutic strategies to improve maternal and fetal long-term health outcomes. This review provides an overview of weight loss interventions and discusses their use in the context of gestation, such as surgical interventions and anti-obesity medications. As the interest in incretin-based therapies has risen substantially, we discuss how incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and GLP-1 receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) dual agonists, might improve reproductive function and could interact with the physiological metabolic changes ensuring a healthy pregnancy. These metabolic adaptations during pregnancy arise from the integration of insulin signaling, lipid metabolism, placental endocrine function, mitochondrial remodeling and inflammatory regulation. Furthermore, we consider not only short-term consequences of maternal overweight and obesity but also focus on fetal long-term health trajectories following pregnancy-related metabolic disorders, as maternal obesity and gestational weight gain are considered risk factors for childhood obesity and overweight.


  • Open Access

    Internal and external validation of a machine learning algorithm to detect preeclampsia-related adverse outcomes in high-risk pregnancies

    by Max Hackelöer, Oliver Rieger, Sunitha Suresh, Ariel Mueller, Ameli Hoyler, Leon Schmidt, Mark Neznansky, Lisa Lorenz-Meyer, Wolfgang Henrich, Sarosh Rana, et al.


  • Open Access

    Validation of a machine-learning-based algorithm to predict preeclampsia-related adverse outcomes on a real-world dataset

    by Ameli Hoyler, Oliver Rieger, Max Hackelöer, Mark Neznansky, Wolfgang Henrich, Lisa Lorenz-Meyer, Stefan Verlohren

    Purpose: Preeclampsia is a major obstetric disorder. Machine learning (ML) models incorporating angiogenic biomarkers show promise in predicting related adverse outcomes, but refinement is needed for clinical use. This study aimed to reduce features to a clinically meaningful set and to develop and validate predictive endpoints for preeclampsia-associated outcomes. Methods: A model with a reduced feature set was derived from a training cohort of 1,634 patients (2, 412 visits) and then tested on a validation cohort of 402 patients (540 visits). Three machine learning models were developed to predict (1) adverse outcomes overall, (2) delivery within 14 days before 34 weeks of gestation, and (3) delivery within 7 days after 34 weeks, using 13 features versus 114 originally. Results: Reduced-feature models demonstrated comparable accuracy to original models across all endpoints. Model 1 (any adverse outcome) achieved an Area Under the Receiver Operating Characteristic Curve (AUROC) of 0.92 (95% CI: 0.88–0.96) in training and 0.89 (95% CI: 0.84–0.93, p = 0.31) in the validation cohort, respectively. For delivery within 14 days, the AUROC was 0.92 (95% CI: 0.87–0.96) in training and 0.85 (95% CI: 0.78–0.92) in validation ( p = 0.13). Delivery within 7 days showed AUROCs of 0.79 (95% CI: 0.70–0.87) and 0.80 (95% CI: 0.75–0.85) ( p = 0.78). Conclusion: A machine learning model with a significantly reduced number of features can accurately predict clinically relevant preeclampsia outcomes. The identified endpoints (timing of delivery and adverse events) could support clinical decision-making and help reduce maternal and neonatal morbidity and mortality.


  • Open Access

    Preemptive immunotherapy for fetal acetylcholine receptor antibody disorder (FARAD): from recurrent pregnancy losses to a healthy infant - a case report

    by Stefan Verlohren, Christof Dame, Beate Mayer, Iris Dressler-Steinbach, Claus-Eric Ott, Inga Koneczny, Marlene Wolfsgruber, Sarah Hoffmann, Andreas Meisel

  • Open Access

    Circulating Plasma Syncytin-1 mRNA in Preeclampsia—A Pilot Study

    by Lisa Lorenz-Meyer, Christoph Bührer, Stefan Verlohren, Stefanie Endesfelder

    The endogenous human retroviral protein syncytin-1 is vital for placental integrity via syncytiotrophoblast formation. Preeclampsia has been associated with reduced placental syncytin-1 expression. The goal of the prospective pilot study was to investigate the role of circulating fetal syncytin-1 mRNA in women with and without preeclampsia (PE). We therefore determined syncytin-1 mRNA in maternal plasma of n = 26 women without and n = 43 women with PE with quantitative real-time PCR. Median circulating syncytin-1 mRNA concentrations were significantly lower in women with PE [1 217 050 copies; IQR 610 900–1 482 069] vs. those without PE [1 992 739 copies; IQR 1 616 811–3 126 225], p < 0.001. The area under the receiver operating curve used to diagnose PE at the time of delivery was 0.913 (95% CI: 0.850–0.977). Sub-analysis of patients with PE at sampling and patients who later developed PE vs. gestational-age-matched controls yielded a diagnostic accuracy of fetal syncytin-1 expression with an AUC of 0.962 (95% CI 0.877–1.000) and a predictive accuracy of 0.924 (95% CI 0.842–0.983). Quantification of the fetal syncytin-1 expression in maternal plasma might be used as a diagnostic and predictive tool in PE.


  • Top Cited Papers
    Open Access

    Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia

    by Olivia Nonn, Olivia Debnath, Daniela S. Valdes, Katja Sallinger, Ali Kerim Secener, Cornelius Fischer, Sebastian Tiesmeyer, Jose Nimo, Thomas Kuenzer, Juliane Ulrich, et al.

    BACKGROUND: Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce. METHODS: To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation. RESULTS: We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis. CONCLUSIONS: This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.


  • Open Access

    Accuracy of prenatal detection of facial clefts and relation between facial clefts, additional malformations and chromosomal abnormalities: a large referral-center cohort

    by Florence Vibert, Guel Schmidt, Kerstin Löffler, Adam Gasiorek-Wiens, Wolfgang Henrich, Stefan Verlohren

    Purpose: Facial clefts belong to the most common congenital malformations and their prenatal diagnosis is a constant challenge. The aim of this study was to determine the accuracy of prenatal ultrasound in correctly classifying facial clefts. Furthermore, we aimed to specify the distribution of the type of clefts and underlying genetic conditions. Methods: All fetuses seen with suspected facial cleft in the Department of Obstetrics, Charité – Universitätsmedizin Berlin during a period of 23 years (1999–2022) were included in this retrospective study. Clefts were classified according to the classification of Nyberg. All additional prenatal findings were assessed and correlated with the outcome. The accuracy of prenatal diagnosis was assessed. Results: 292 patients were included in the study. The most common type of clefts were unilateral cleft lip and palate (CL-P) (53.6%) and bilateral CL-P (30.6%), followed by CL (8.1%), CP (5.1%) and median CL-P (2.6%). The overall pre- and postnatal concordance rate corresponding to a correct prenatal diagnosis was high, 88.9%, ranging from 73.7% (CL) to 93.7% (unilateral CL-P). Most of the median clefts (95.2%) and CP (93.3%) were associated with other sonographic abnormalities, as well as 52.2% of bilateral CL-P. Chromosomal abnormalities, mostly trisomy 13 and trisomy 18, were observed in in the median CL-P (47.6%), bilateral CL-P (31.1%) and CP (26.7%) groups, in contrast to the CL (9.1%) and unilateral CL-P (12.9%) groups. It was exceptional to have a chromosomal abnormality without additional malformations (4.8%). The mortality rate including one late miscarriage, 5 IUFD’s, 74 TOPs and 6 palliative cares at birth was 29.8%, particularly high for median clefts (90.5%). Conclusion: Prenatal ultrasound exhibited a high accuracy to assess the type of facial clefts with an average rate of 88.9% (73.7%–93.7%) and a concordance rate of up to 93.7%, depending on the type of cleft. The search for additional malformations as well as clarifying underlying genetic conditions is essential. This allows for a targeted counseling of the parents and to best prepare for postnatal care, including surgery by the maxillofacial team.


  • Comparison of the Soluble fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio Alone versus a Multi-Marker Regression Model for the Prediction of Preeclampsia-Related Adverse Outcomes after 34 Weeks of Gestation

    by Dorota Sroka, Lisa-Antonia Lorenz-Meyer, Valerie Scherfeld, Julie Thoma, Andreas Busjahn, Wolfgang Henrich, Stefan Verlohren

    Introduction: The objective of this retrospective study was to compare the predictive performance of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio alone or in a multi-marker regression model for preeclampsia-related maternal and/or fetal adverse outcomes in women >34 weeks of gestation. Methods: We analyzed the data collected from 655 women with suspected preeclampsia. Adverse outcomes were predicted by multivariable and univariable logistic regression models. The outcome of patients was evaluated within 14 days after presentation with signs and symptoms of preeclampsia or diagnosed preeclampsia. Results: The full model integrating available, standard clinical information and the sFlt-1/PlGF ratio had the best predictive performance for adverse outcomes with an AUC of 72.6%, which corresponds to a sensitivity of 73.3% and specificity of 66.0%. The positive predictive value of the full model was 51.4%, and the negative predictive value was 83.5%. 24.5% of patients, who did not experience adverse outcomes but were classified as high risk by sFlt-1/PlGF ratio (≥38), were correctly classified by the regression model. The sFlt-1/PlGF ratio alone had a significantly lower AUC of 65.6%. Conclusions: Integrating angiogenic biomarkers in a regression model improved the prediction of preeclampsia-related adverse outcomes in women at risk after 34 weeks of gestation.